Creg J Workman

Title: Creg J Workman: Innovator in Cancer Treatment

Introduction

Creg J Workman is a notable inventor based in Memphis, TN (US), recognized for his significant contributions to cancer treatment through innovative antibody therapies. With a total of 7 patents to his name, Workman has made strides in enhancing T cell immune responses in cancer patients.

Latest Patents

His latest patents include groundbreaking methods aimed at increasing T cell immune response in the treatment of cancer. One of his notable inventions is a method that combines anti-cancer antibodies and inhibitory antibodies to CD223, which helps overcome immune suppression in cancer patients. The inhibitory antibodies can be generated in an animal by injecting fragments of CD223. These antibodies may take the form of monoclonal antibodies, single chain antibodies, or humanized antibodies. Another significant patent involves methods for treatment that comprise an antibody binding to the CD223 protein, where anti-CD223 antibodies are designed to counteract immune suppression in cancer patients. Similar to the previous patent, these antibodies can also be generated through the injection of fragments of CD223.

Career Highlights

Creg J Workman has had a distinguished career, working with esteemed institutions such as St. Jude Children's Research Hospital and The Johns Hopkins University. His work has been pivotal in advancing the field of immunotherapy for cancer treatment.

Collaborations

Throughout his career, Workman has collaborated with prominent figures in the field, including Dario A Vignali and Drew M Pardoll. These collaborations have further enriched his research and innovations.

Conclusion

Creg J Workman stands out as a leading inventor in the realm of cancer treatment, with a focus on innovative antibody therapies that enhance immune responses. His contributions continue to impact the field significantly.